Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.77 |
| ▸ | MMP14 | P50281 | 10/20 | 0.65 |
| ▸ | MMP12 | P39900 | 5/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74330 | 1.00 | MMP13 (0.77) | MMP13MMP14MMP12KCNH2 | |
| SCHEMBL74550 | 0.90 | MMP13 (0.77) | MMP13MMP14MMP12KCNH2 | |
| SCHEMBL5349571 | 0.88 | MMP13 (0.69) | MMP13MMP14MMP12KCNH2 | |
| SCHEMBL74232 | 0.87 | MMP13 (0.77) | MMP13MMP14MMP12KCNH2 | |
| SCHEMBL88026 | 0.87 | MMP13 (0.77) | MMP13MMP14MMP12KCNH2 | |
| SCHEMBL74255 | 0.87 | MMP13 (0.77) | MMP13MMP14MMP12KCNH2 | |
| SCHEMBL76111 | 0.87 | MMP13 (1.00) | MMP13MMP14MMP12KCNH2 | |
| SCHEMBL74593 | 0.84 | MMP13 (0.78) | MMP13MMP14MMP12KCNH2 | |
| SCHEMBL76108 | 0.83 | MMP13 (0.71) | MMP13MMP14MMP12KCNH2 | |
| SCHEMBL12945860 | 0.79 | MMP13 (1.00) | MMP13MMP14MMP12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129412-B2 | Hydantoin derivatives useful as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | claimed |
| EP-1828166-B1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | claimed |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| US-8129412-B2 | Hydantoin derivatives useful as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-1828166-B1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | MMP3, MMP9, MMP2 | MMP13 13/4885MMP14 10/4885MMP12 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.